[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"3M Unitek Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":97},{"warningLetters":4,"total":96},[5,32,54,74],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},528,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-10T04:00:00Z\">10\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Facme-united-corporation-712324-10102025\">Acme United Corporation\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-03\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Walter C. Johnsen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Acme United Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Waterview Drive Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shelton\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06484\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-03\u003C\u002Fp>\u003Cp>October 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Johnsen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Acme United Corporation, FEI 3012129555, at 301 Marianne St., Shelton, CT, from March 18 to 28, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 18, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. Your firm also failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.63 and 21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm used \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as a component to manufacture your topical over-the-counter (OTC) drug products, such as antiseptic wipes, labeled as sterile and non-sterile. You failed to adequately design and control your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system to ensure that it was suitable for producing water used in the formulation of your drug products. For example, you isolated the objectionable microorganism \u003Cem>Burkholderia cepacia (B. cepacia)\u003C\u002Fem> on numerous occasions within the holding tank and at the point of use. You regularly sanitized your water system after recovering \u003Cem>B. cepacia\u003C\u002Fem>, yet you continued to recover \u003Cem>B. cepacia\u003C\u002Fem> shortly after those repeated sanitization cycles. Microbiological monitoring of your system also yielded several “too numerous to count” results at multiple points in the system. These data indicated the presence of a recalcitrant biofilm. Furthermore, your firm failed to conduct timely and comprehensive investigations into these out-of-limit (OOL) microbiological results, including documenting root cause determinations and product impact assessment.\u003C\u002Fp>\u003Cp>We acknowledge you recently installed a new water system. We note that this system, based on discussions during our inspection, appears to be an on-demand system without continuous circulation.\u003C\u002Fp>\u003Cp>In your response, you state you do not believe your products pose a safety risk to consumers. For your non-sterile drug products, you indicate that there is a low potential impact to the end user because little to no microbial contamination was recovered from batch samples. You also indicate the active ingredient has an anti-microbial effect. Your response is inadequate. Antimicrobial formulations are not a substitute for adequate CGMP. Additionally, it is important to note that microbial contamination is not uniformly distributed, and samples may not be representative of the type or level of contamination that may exist within an entire system.\u003C\u002Fp>\u003Cp>Your new water system continues to have deficient elements that do not assure long-term system reliability and suitable water quality. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system must be adequately designed and properly maintained to minimize the potential for contamination. For example, stagnant water from an on-demand, non-recirculating system can foster the development of biofilms. \u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your water system design, control, and maintenance. Regarding system control, for example, explain whether your firm is utilizing a recirculating water system and whether heat is an element of the system. In addition, state the duration, if any, that your water system is continuously circulating, and provide your rationale for any duration less than 24 hours.\u003C\u002Fli>\u003Cli>A thorough independent assessment to ensure you have installed and are operating a suitable water system, accompanied by a remediation plan to address any identified deficiencies. Also, include a robust ongoing control, maintenance, and monitoring program to ensure the new system consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications, and appropriate microbial limits.\u003C\u002Fli>\u003Cli>Regarding the latter, ensure that your total microbial count limits and objectionable microbiological standards for water are appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\u003Cli>An updated risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions\u003Cbr>that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full microbiological testing of retain samples of your non-sterile finished drug products to determine the quality of all batches of drug product distributed to the United States that are within expiry. You should test all appropriate quality attributes including, but not limited to, microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A summary of all data from all (e.g., accelerated, annual) stability studies from the last five years. Include all lots, all timepoints, and any out-of-specification (OOS) results, irrespective of whether they were later invalidated.\u003C\u002Fli>\u003Cli>A summary table of all individual microbial test results (total counts and identification of bioburden to detect any objectionable microbes) obtained from testing samples from your new water system. Also, include all physical and chemical test results (total organic carbon, conductivity, etc.)\u003C\u002Fli>\u003Cli>A retrospective review of all invalidated OOL water test results, including the following for each OOL:\u003Cbr>• For all OOL results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS\u002FOOL result investigation systems. The corrective action and preventative action (CAPA) should include but not be limited to addressing the following:\u003Cbr>• Quality unit oversight of laboratory investigations\u003Cbr>• Identification of adverse laboratory control trends\u003Cbr>• Resolution of causes of laboratory variation\u003Cbr>• Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>• Adequately scoping of each investigation and its CAPA\u003Cbr>• Revised OOS\u002FOOL investigation procedures with these and other remediations\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. Your firm also failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.100(a) and 21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your production and process controls used in the manufacture of your drug products. Additionally, you failed to conduct adequate qualification activities for equipment used to manufacture your drug products.\u003C\u002Fp>\u003Cp>Furthermore, your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that included validation of all sterilization processes. For example, your firm has not performed quarterly dose audit studies to monitor the \u003Cstrong>(b)(4)\u003C\u002Fstrong> dose to ensure that it remains effective for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of your drug products intended to be sterile.\u003C\u002Fp>\u003Cp>In your response, you state that you will develop and implement enhanced process controls and complete process validation studies. Your response is inadequate as it did not provide a timeframe for completion of process validation activities for each of your drug products. In addition, your response did not include your interim plan for any drugs distributed before validation activities are completed to ensure you produce drug products of acceptable quality.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem>, for general principles and approaches that the FDA considers appropriate elements of process validation at\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. As part of your response, explain how you handle changes throughout the lifecycle, including determining whether any changes (e.g., materials, manufacturing process, atypical bioburden) adversely impact the effectiveness of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process. Finally, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A list of all quality complaints for the past five years. Include the batch number, name of product, lot size, whether a complaint sample was received (if not, explain why), and description of any associated CAPA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.167(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm released your finished OTC drug products to the U.S. market without testing each batch for all appropriate quality attributes. For example, your firm distributed multiple batches of purportedly sterile finished drug products without conducting sterility testing. Without testing all appropriate physical and microbiological quality attributes of your drug products, your quality unit lacks essential safety information required to make suitable batch release decisions.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that you did not begin sterility testing on your drug products until the end of 2024. You indicate that you will test the retains, per USP &lt;71&gt; Sterility Tests, of lots for which you have retains.\u003C\u002Fp>\u003Cp>Your response is inadequate because you have not provided proof of method suitability of the sterility test performed by your contract laboratory to ensure its capability to detect microbes in your finished drug product. Additionally, you have failed to indicate if there are batches for which you lack retains and are therefore unable to test for sterility.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, documentation, supervision, and analyst competencies. Based on this review, provide a detailed CAPA plan to remediate your laboratory system. If a contract facility performs any laboratory functions on your behalf, conduct an equivalent comprehensive assessment of their practices, implement an appropriate supplier CAPA, monitor the remediations at the contractor, and provide a summary of these planned CAPA activities.\u003C\u002Fli>\u003Cli>A summary of all test results obtained from testing your batch retains, including any OOS\u002FOOL results obtained (irrespective of whether later invalidated). Also include a list of batches for which you have no retains and are unable to test for sterility.\u003C\u002Fli>\u003Cli>A list of microbial test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.\u003C\u002Fli>\u003Cli>Method suitability tests performed for each of your formulations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see these FDA guidance documents:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\u003C\u002Fli>\u003Cli>\u003Cem>Q9 Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management\u003C\u002Fli>\u003Cli>\u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012129555 and ATTN: Nancy Scheraga.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-03\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Walter C. Johnsen\n\nRecipient Title\n\nCEO\n\nAcme United Corporation\n\n1 Waterview Drive Suite 200\n\nShelton, CT 06484\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-03\nOctober 10, 2025\nDear Mr. Johnsen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Acme United Corporation, FEI 3012129555, at 301 Marianne St., Shelton, CT, from March 18 to 28, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 18, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. Your firm also failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.63 and 21 CFR 211.192).\nYour firm used (b)(4) water as a component to manufacture your topical over-the-counter (OTC) drug products, such as antiseptic wipes, labeled as sterile and non-sterile. You failed to adequately design and control your (b)(4) water system to ensure that it was suitable for producing water used in the formulation of your drug products. For example, you isolated the objectionable microorganism Burkholderia cepacia (B. cepacia) on numerous occasions within the holding tank and at the point of use. You regularly sanitized your water system after recovering B. cepacia, yet you continued to recover B. cepacia shortly after those repeated sanitization cycles. Microbiological monitoring of your system also yielded several “too numerous to count” results at multiple points in the system. These data indicated the presence of a recalcitrant biofilm. Furthermore, your firm failed to conduct timely and comprehensive investigations into these out-of-limit (OOL) microbiological results, including documenting root cause determinations and product impact assessment.\nWe acknowledge you recently installed a new water system. We note that this system, based on discussions during our inspection, appears to be an on-demand system without continuous circulation.\nIn your response, you state you do not believe your products pose a safety risk to consumers. For your non-sterile drug products, you indicate that there is a low potential impact to the end user because little to no microbial contamination was recovered from batch samples. You also indicate the active ingredient has an anti-microbial effect. Your response is inadequate. Antimicrobial formulations are not a substitute for adequate CGMP. Additionally, it is important to note that microbial contamination is not uniformly distributed, and samples may not be representative of the type or level of contamination that may exist within an entire system.\nYour new water system continues to have deficient elements that do not assure long-term system reliability and suitable water quality. The (b)(4) water system must be adequately designed and properly maintained to minimize the potential for contamination. For example, stagnant water from an on-demand, non-recirculating system can foster the development of biofilms. (b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn response to this letter, provide:\nA comprehensive assessment of your water system design, control, and maintenance. Regarding system control, for example, explain whether your firm is utilizing a recirculating water system and whether heat is an element of the system. In addition, state the duration, if any, that your water system is continuously circulating, and provide your rationale for any duration less than 24 hours.\nA thorough independent assessment to ensure you have installed and are operating a suitable water system, accompanied by a remediation plan to address any identified deficiencies. Also, include a robust ongoing control, maintenance, and monitoring program to ensure the new system consistently produces water adhering to (b)(4) Water, USP monograph specifications, and appropriate microbial limits.\nRegarding the latter, ensure that your total microbial count limits and objectionable microbiological standards for water are appropriate in view of the intended use of the products produced by your firm.\nAn updated risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions\nthat you will take in response to the risk assessment, such as customer notifications and product recalls.\nAn action plan and timelines for conducting full microbiological testing of retain samples of your non-sterile finished drug products to determine the quality of all batches of drug product distributed to the United States that are within expiry. You should test all appropriate quality attributes including, but not limited to, microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOL result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA summary of all data from all (e.g., accelerated, annual) stability studies from the last five years. Include all lots, all timepoints, and any out-of-specification (OOS) results, irrespective of whether they were later invalidated.\nA summary table of all individual microbial test results (total counts and identification of bioburden to detect any objectionable microbes) obtained from testing samples from your new water system. Also, include all physical and chemical test results (total organic carbon, conductivity, etc.)\nA retrospective review of all invalidated OOL water test results, including the following for each OOL:\n• For all OOL results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS\u002FOOL result investigation systems. The corrective action and preventative action (CAPA) should include but not be limited to addressing the following:\n• Quality unit oversight of laboratory investigations\n• Identification of adverse laboratory control trends\n• Resolution of causes of laboratory variation\n• Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n• Adequately scoping of each investigation and its CAPA\n• Revised OOS\u002FOOL investigation procedures with these and other remediations\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. Your firm also failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.100(a) and 21 CFR 211.113(b)).\nYou failed to adequately validate your production and process controls used in the manufacture of your drug products. Additionally, you failed to conduct adequate qualification activities for equipment used to manufacture your drug products.\nFurthermore, your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that included validation of all sterilization processes. For example, your firm has not performed quarterly dose audit studies to monitor the (b)(4) dose to ensure that it remains effective for the (b)(4) sterilization of your drug products intended to be sterile.\nIn your response, you state that you will develop and implement enhanced process controls and complete process validation studies. Your response is inadequate as it did not provide a timeframe for completion of process validation activities for each of your drug products. In addition, your response did not include your interim plan for any drugs distributed before validation activities are completed to ensure you produce drug products of acceptable quality.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, Process Validation: General Principles and Practices, for general principles and approaches that the FDA considers appropriate elements of process validation at\nhttps:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. As part of your response, explain how you handle changes throughout the lifecycle, including determining whether any changes (e.g., materials, manufacturing process, atypical bioburden) adversely impact the effectiveness of your (b)(4) sterilization process. Finally, include your program for qualification of your equipment and facility.\nA list of all quality complaints for the past five years. Include the batch number, name of product, lot size, whether a complaint sample was received (if not, explain why), and description of any associated CAPA.\n3. Your firm failed to conduct appropriate laboratory testing to determine whether each batch of drug product purporting to be sterile conforms to such requirements (21 CFR 211.167(a)).\nYour firm released your finished OTC drug products to the U.S. market without testing each batch for all appropriate quality attributes. For example, your firm distributed multiple batches of purportedly sterile finished drug products without conducting sterility testing. Without testing all appropriate physical and microbiological quality attributes of your drug products, your quality unit lacks essential safety information required to make suitable batch release decisions.\nIn your response, you acknowledge that you did not begin sterility testing on your drug products until the end of 2024. You indicate that you will test the retains, per USP \u003C71> Sterility Tests, of lots for which you have retains.\nYour response is inadequate because you have not provided proof of method suitability of the sterility test performed by your contract laboratory to ensure its capability to detect microbes in your finished drug product. Additionally, you have failed to indicate if there are batches for which you lack retains and are therefore unable to test for sterility.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, documentation, supervision, and analyst competencies. Based on this review, provide a detailed CAPA plan to remediate your laboratory system. If a contract facility performs any laboratory functions on your behalf, conduct an equivalent comprehensive assessment of their practices, implement an appropriate supplier CAPA, monitor the remediations at the contractor, and provide a summary of these planned CAPA activities.\nA summary of all test results obtained from testing your batch retains, including any OOS\u002FOOL results obtained (irrespective of whether later invalidated). Also include a list of batches for which you have no retains and are unable to test for sterility.\nA list of microbial test methods and specifications used to analyze each batch of your drug product before making a batch disposition decision, and the associated written procedures.\nMethod suitability tests performed for each of your formulations.\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see these FDA guidance documents:\nQ8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\nQ9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management\nQ10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012129555 and ATTN: Nancy Scheraga.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Acme United Corporation","acme-united-corporation-712324-10102025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Facme-united-corporation-712324-10102025","2026-10-26T08:07:49.760932+00:00","Warning Letter","Issued","2025-10-21","712324","Drugs","Mr. Walter C. Johnsen","2026-08-19T16:13:12.783+00:00","VIA UPS","320-26-03","2025-10-10",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":19,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2046,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-06-22T16:45:00Z\">06\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-16T04:00:00Z\">06\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-zone-store-661352-06162023\">United Zone Store\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2301956\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>United Zone Store\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 Capcom Ave, STE 9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wake Forest\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27587\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:unitedzonestore@gmail.com\"> unitedzonestore@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 16, 2023\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>To Whom it May Concern:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Funitedzonestore.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. &nbsp;Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. &nbsp;See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. &nbsp;Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. &nbsp;For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Funitedzonestore.com revealed that you offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: ELF Bar BC5000 Disposable Vape – Gumi, and ELF Bar BC5000 Disposable Vape – Lemon Mint. &nbsp;\u003C\u002Fp>\n\n\u003Cp>These ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. &nbsp;All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&amp;C Act. &nbsp;It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301956, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>United Zone E-Cigarette &amp; Cigar\u003Cbr>\n7332 Creedmore Rd\u003Cbr>\nRaleigh, NC\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2301956\n\nProduct:\n\nTobacco\n\nRecipient:\n\nUnited Zone Store\n\n109 Capcom Ave, STE 9\n\nWake Forest, NC 27587\n\nUnited States\n\nunitedzonestore@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 16, 2023\n\nWARNING LETTER\n\nTo Whom it May Concern:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Funitedzonestore.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Funitedzonestore.com revealed that you offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: ELF Bar BC5000 Disposable Vape – Gumi, and ELF Bar BC5000 Disposable Vape – Lemon Mint.\n\nThese ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301956, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nUnited Zone E-Cigarette & Cigar\n\n7332 Creedmore Rd\n\nRaleigh, NC\n\nShopify, Inc.\n\nabuse@shopify.com","United Zone Store","united-zone-store-661352-06162023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-zone-store-661352-06162023","2026-10-26T08:10:17.818112+00:00","2023-06-22","661352","Tobacco","2026-08-20T01:02:29.165+00:00","VIA UPS and Electronic Mail","RW2301956","2023-06-16",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":18,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},894,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-24T04:00:00Z\">03\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025\">United Health Products, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Bioresearch Monitoring Program\u002FInstitutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Thom\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>United Health Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>520 Fellowship Road, Suite #D-406\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mt. Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@uhpcorp.com\"> (b)(6)@uhpcorp.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Thom:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\u003C\u002Fp>\u003Cp>The inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\u003C\u002Fp>\u003Cp>You conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and FDA meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\u003C\u002Fp>\u003Cp>FDA maintains that the study UHP0001 that you have conducted to support \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where you inserted the word “NSR” in describing the name of the study and removed references to a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\u003C\u002Fp>\u003Cp>b. You did not maintain adequate documentation regarding those monitoring activities that did occur:\u003C\u002Fp>\u003Cp>i. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\u003C\u002Fp>\u003Cp>ii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\u003C\u002Fp>\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\u003C\u002Fp>\u003Cp>b. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\u003C\u002Fp>\u003Cp>Securing clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>b. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\u003C\u002Fp>\u003Cp>Proper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\u003C\u002Fp>\u003Cp>Finally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> investigational device units packaged.\u003C\u002Fp>\u003Cp>b. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\u003C\u002Fp>\u003Cp>Proper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\u003C\u002Fp>\u003Cp>This was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Soma Kalb, PhD\u003Cbr>Director\u003Cbr>Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nBiologics\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrian Thom\n\nRecipient Title\n\nCEO\n\nUnited Health Products, Inc.\n\n520 Fellowship Road, Suite #D-406\n\nMt. Laurel, NJ 08054\n\nUnited States\n\n(b)(6)@uhpcorp.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWarning Letter\nMarch 24, 2025\nDear Mr. Thom:\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at United Health Products, Inc. from September 23, 2024, to October 4, 2024, by an investigator from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting,” for CelluSTAT Absorbable HemoStat, Premarket Approval (PMA) Application, (b)(4), complied with applicable federal regulations. The CelluSTAT Absorbable Hemostat is a device as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited and discusses your written response, dated October 25, 2024, to the noted violations.\nThe inspection was conducted under the Bioresearch Monitoring (BIMO) Program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDEs), PMA applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions and 21 CFR Part 50 - Protection of Human Subjects, which concern requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you. The deviations noted on Form FDA-483, your written response, and our subsequent review of the inspection report are discussed below:\n1. Failure to submit an IDE application to FDA and failure to obtain FDA approval prior to beginning an investigation for which FDA’s approval is required [21 CFR 812.20(a)(1) and (2).\nSponsors must submit an IDE application to the FDA if the sponsor intends to use a significant risk device in a clinical investigation. In addition, a sponsor may not begin an investigation for which FDA’s approval of an application is required until FDA has approved the application. You did not submit an IDE application to FDA or obtain FDA approval prior to beginning such an investigation.\nYou conducted your study, UHP001, without submission and approval of an IDE application to FDA. The Western Copernicus Group (WCG) Institutional Review Board (IRB) determined that the procedures in the research posed a potential significant risk to subjects and requested documentation of the FDA’s non-significant risk (NSR) determination in multiple communications. You provided to the IRB FDA written feedback for (b)(4) and FDA meeting minutes for (b)(4), which had been modified from the FDA official correspondence by removal of references to future IDE submission and by addition of language that purported to indicate FDA agreement that the study was non-significant risk (NSR). In particular, you provided the transmittal email from FDA along with these meeting minutes, which imply that the meeting minutes that you submitted to the IRB were those provided by FDA to you as the official record. The IRB used this documentation, which misrepresented the FDA risk determination for this study, to support their determination of the regulatory status of the study, and to review and approve this study without FDA oversight.\nFDA maintains that the study UHP0001 that you have conducted to support (b)(4) as a Class III device is considered a significant risk device clinical investigation for which you should have submitted an IDE application to FDA and obtained FDA approval prior to initiation. Your device is an absorbable hemostat intended to be used as an adjunct to primary hemostasis in surgical procedures to assist in controlling capillary, venous and small arterial hemorrhage when other conventional methods are ineffective or impractical. Absorbable hemostatic agents are intended to be absorbed into the body and are Class III devices per 21 CFR 878.4490. The agency considers such devices to be significant risk devices because they are absorbed internally and present “a potential for serious risk to the health, safety, or welfare of a subject” per 21 CFR 812.3(m). 21 CFR 812.20(a) requires any sponsor who intends to use a significant risk device in an investigation to submit an application to FDA, and to wait to begin the investigation until FDA has approved the application. FDA approval of an IDE application helps to ensure subject safety and that the risks associated with the device and study procedures are minimized.\nThis was conveyed to you in the Form FDA-483, and your response dated October 25, 2024 is inadequate. Your written response includes a discussion of the interactions with FDA regarding this study and describes your misunderstanding of those interactions and of NSR\u002Fsignificant risk studies. It indicates that the meeting minutes for (b)(4) that you had provided to the IRB were your modifications to the minutes received from FDA and that you had informally emailed them to FDA. However, there is no record of your submission of these revised meeting minutes to FDA either by email or with a Meeting Minutes Disagreement amendment, the procedure outlined in FDA’s transmittal email for handling changes to meeting minutes. Importantly, there is also no agreement by FDA on these meeting minutes that you had revised. Your response also does not speak to the modifications that were made to the official FDA correspondence for (b)(4), where you inserted the word “NSR” in describing the name of the study and removed references to a (b)(4). FDA is greatly concerned about your misrepresentation of the FDA’s stance regarding the risk determination of the study to the IRB, which resulted in you inappropriately conducting this study without submitting and obtaining approval of an IDE application from FDA prior to initiation.\n2. Failure to ensure proper monitoring of the investigation [21 CFR 812.40].\nSponsors are responsible for ensuring that a clinical investigation is properly monitored. However, you failed to properly monitor your clinical investigation. Examples include, but are not limited to, the following:\na. Although you had described in the study protocol, UHP001, sections 10 and 14.9, that details regarding monitoring would be provided in the study specific Monitoring Plan and clinical site monitoring would be documented in a Clinical Monitoring Plan (CMP), respectively, you did not have an effective and implemented CMP during study conduct.\nb. You did not maintain adequate documentation regarding those monitoring activities that did occur:\ni. You failed to maintain adequate site initiation visit (SIV) documentation for the two clinical investigation sites. There were several discrepancies in documentation of SIV Monitoring Visit Reports, investigator site’s personnel training logs (SIV Training Logs), and Site Visit Logs. For example, the SIV Monitoring Visit Report for site 01 documented the visit was held on-site on December 17, 2018, with the clinical investigator and research coordinator. However, the SIV Training Log for site 01 documented the clinical investigator received SIV training on December 10, 2018, and the research coordinator received SIV training on March 19, 2019. The Site Visit Log for site 01 documented a single SIV date as December 19, 2018.\nii. You failed to maintain adequate interim monitoring documentation for the two clinical investigation sites. For example, the Site Visit Log for site 01 documented the interim monitoring visit was held on-site on July 9, 2019, but there was no interim monitoring report for this visit. In addition, the site visit log for site 02 documented the interim monitoring visit was held on-site on September 10, 2019, but there was no interim monitoring report for this visit.\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a retrospectively-created CMP, new Standard Operating Procedures (SOPs) for clinical monitoring, clinical site selection, and site initiation, and revised Site Visit Logs for both clinical investigation sites. Your response indicates that the retrospectively-created CMP reflects the monitoring practices that were followed during the study conduct and indicates that the updated Site Visit Log added visits that occurred for SIV training for both clinical investigation sites, but were not present on the initial Site Visit Log. You did not provide SIV Monitoring Visit Reports for the additional SIV training conducted for both clinical investigation sites that were added to the Site Visit Logs. You also did not provide the interim monitoring reports for both clinical investigation sites that document the activities that occurred during the interim monitoring visits, nor did you provide the follow-up communication to the investigator\u002Fstudy personnel that discusses visit findings, outstanding action items, and requests for additional information. These items are needed to assess the adequacy of the monitoring conducted for this study.\n3. Failure to secure clinical investigator’s compliance with the signed agreement, the investigational plan, applicable FDA regulations, and any other conditions of approval imposed by the reviewing IRB or FDA, or if compliance could not be obtained, failure to discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation [21 CFR 812.46(a)].\nAs part of monitoring responsibilities, a sponsor is responsible for securing the investigator’s compliance with the investigational plan to ensure adherence with the study protocol and other regulatory requirements. You failed to obtain and secure the clinical investigator’s compliance with the investigational plan and applicable FDA regulations. Examples include, but are not limited to, the following:\na. Forty (40) subjects had baseline laboratory results indicating thrombocytopenia or no baseline platelet laboratory results. As a result, these subjects met exclusion criterion # 9, which lists subjects with a coagulation disorder, thrombocytopenia, liver disease and anti-thrombin therapy as not eligible for study. You did not ensure that investigators properly enrolled subjects according to the investigational plan.\nb. According to your Protocol Deviation Log, there were three (3) subjects whose informed consent forms were not signed by the subject, which violates inclusion criterion # 4, as well as 21 CFR 812.100, which requires that investigators obtain informed consent in accordance with 21 CFR Part 50. You did not ensure that investigators obtained informed consent according to the investigational plan and applicable FDA regulations.\nSecuring clinical investigator compliance is a critical component of monitoring and is critical for ensuring the safety and welfare of study subjects. Failure to secure compliance impacts the reliability and quality of the data resulting from the study and in turn adversely impacts FDA’s ability to assess the overall safety and effectiveness of the device. As you failed to conduct proper monitoring, you did not identify that enrollment criteria were violated or that informed consent was not properly obtained, and also did not take steps to secure compliance with these requirements. Having failed to secure the investigator’s compliance, you also did not discontinue shipments of the device to the investigator and terminate the investigator’s participation in the investigation.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. While your response acknowledged the issue of enrolling subjects that did not meet the eligibility criteria related to thrombocytopenia and provided a comprehensive corrective action and preventative action plan, you have not addressed the issue of failing to obtain informed consent. Specifically, you did not provide any root cause analysis regarding the informed consent protocol deviations. You also did not identify any corrective or preventative actions taken to ensure that informed consent is properly obtained by investigators such that human subjects are adequately protected.\n4. Failure to immediately conduct an evaluation of any unanticipated adverse device effects and failure to report results of such an evaluation to FDA and to all reviewing IRB’s and participating investigators within 10 working days [21 CFR 812.46(b)(1) and 21 CFR 812.150(b)(1)].\nAs a sponsor, you are responsible for conducting an evaluation of any adverse device effects that are reported as serious and unanticipated to ensure adverse events are adequately recorded and reported, and that appropriate follow-up occurs. You failed to conduct these evaluations. Examples include, but are not limited to, the following:\na. You failed to evaluate the unanticipated adverse device effect (UADE) for subject 02-0074 that occurred on April 30, 2019. Information for this UADE was recorded in an Adverse Event (AE) Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nb. You failed to evaluate the UADE for subject 02-0074 that occurred on May 12, 2019. Information for this UADE was recorded in an AE Form; however, there is no documentation to show that the UADE was evaluated as required by 21 CFR 812.46(b)(1) and study protocol, UHP001, section, 9.8.2.\nProper evaluation of UADEs, as required by 812.46(b)(1), is a critical step in ensuring the safety and welfare of study subjects. Appropriate review and evaluation of UADEs and their resolution allows for any necessary changes to be made to the investigational plan to protect study participants. Furthermore, the regulations under 812.150(b)(1) require that a sponsor who conducts an evaluation of an unanticipated adverse device effect under 812.46(b) report the results of such evaluation to FDA. Proper evaluation and timely reporting to FDA of the result of any evaluation of a UADE is important for FDA’s assessment of the overall safety profile of the device.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response includes a description that the clinical site did not report these AEs to the sponsor as UADEs, and that they therefore were not handled as UADEs. In addition, you provided an updated SOP (CLN-06 Adverse Event Monitoring) to include UADE reporting requirements. However, these documents do not describe how an AE designated as a UADE by an investigator on the AE paper form is reported to the sponsor. It appears that the designation of an AE as a UADE is not captured in the electronic case report form (eCRF) and therefore these two AEs were not reported to the sponsor as UADEs, despite being identified by the investigator as such. As a result, these two AEs were not properly evaluated to determine whether they met the definition of a UADE, as required by the study protocol, UHP001, sections 9.1 and 9.8. Neither the updated SOP nor the protocol provide adequate detail to prevent a recurrence of this scenario in future studies. In addition, you did not provide source documentation for subject 02-0074 that was obtained according to Section 9.4 of the study protocol, UHP001, to assess the causal relationship between the AE and the investigational device. This documentation is needed to ensure that you have adequately conducted an evaluation of reported AEs as expected in the UHP001 study protocol. Although in this case, these two AEs were ultimately determined not to be UADEs through your postinspection activities, timely investigation of UADEs identified by study investigators while the study is ongoing is required by 21 CFR 812.46(b)(1) and a critical element of good clinical practices and does not appear to be assured by your corrective actions.\nFinally, section 7.6.1 of your updated SOP provides UADE reporting requirements and suggests that the requirement only applies to IDE studies. The evaluation requirement under 812.46 and reporting requirement under 812.150(b)(1) for UADEs also apply to non-significant risk studies subject to abbreviated requirements per 812.2(b), not just studies being conducted under an IDE. The regulatory requirements should be clarified and corrected in the SOP.\n5. Failure to maintain accurate, complete, and current device shipment and disposition records [21 CFR 812.140(b)(2)].\nAs a sponsor, you are responsible for maintaining accurate, complete, and current records relating to an investigation. Specifically, records of shipment must include the name and address of the consignee, type and quantity of device, date of shipment, and batch number or code mark, and records of disposition must describe the batch number or code marks of any devices returned to the sponsor, repaired, or disposed of in other ways by the investigator or another person, and the reasons for and method of disposal. You failed to maintain the necessary records. Examples include, but are not limited to, the following:\na. You failed to maintain records of investigational devices received by a sponsor employee, investigational devices returned to the sponsor, or unused investigational devices disposed of for the (b)(4) investigational device units packaged.\nb. You failed to maintain accurate device accountability records for both clinical investigation sites. For example, your Master Device Accountability Log documented that there were 230 subjects who received the investigational device in site # 01 and 4 subjects who received the investigational device in site # 02, with zero returned devices. However, there were only a total of 118 subjects randomized to receive the investigational device and the other subjects were assigned to the control group. In addition, the UHP001 Inventory Log for Site # 02 indicated that only 1 device was used, but the Master Device Accountability Log documented that there were 4 devices used.\nProper records of device shipment and disposition are necessary for control of devices and to confirm that the investigational device is used only by qualified investigators on subjects appropriately enrolled in the study. If the devices were used by unqualified individuals on patients not enrolled in the study, there would be an increased risk of harm to both the user and patient.\nThis was conveyed to you in the Form FDA-483, and your written response dated October 25, 2024 is inadequate. Your response provided a SOP for investigational device management and a corrected Master Accountability Log. However, you did not provide source documentation of study subjects’ randomization assignment to verify the changes made to the Master Accountability Log and to demonstrate that device usage was appropriate.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\nYour response should reference “CTS# (b)(4)” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OII BIMO Division 1 via email OIIBIMODivision1Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn\u002F.\nIf you have any questions, please contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nSoma Kalb, PhD\nDirector\nDivision of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","United Health Products, Inc.","united-health-products-inc-697777-03242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-health-products-inc-697777-03242025","2026-10-26T08:10:17.734231+00:00","2025-05-20","697777","BiologicsMedical Devices","Brian Thom","2026-08-19T16:46:50.292+00:00","2025-03-24",{"id":75,"raw":76,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":18,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":19,"issuing_office":80,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},848,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-07T05:00:00Z\">03\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-king-foods-private-limited-698766-03072025\">United King Foods Private Limited\u003C\u002Fa>","Human Foods Program","Low Acid Canned Food Regulation\u002FAdulterated \u003Cbr \u002F>\r\n","Low Acid Canned Food Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sheikh Muhammad Tehseen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>United King Foods Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Ibrahim Residency, Plot 64, Block 3 C.P &amp; B.C.H.S, Sharfabad Karachi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sindh\u003C\u002Fspan>-\u003Cspan>75850\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pakistan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tehseen@unitedking.com\"> tehseen@unitedking.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 7, 2025\u003C\u002Fp>\u003Cp>Re# 698766\u003C\u002Fp>\u003Cp>Dear Mr. Sheikh Muhammad Tehseen:\u003C\u002Fp>\u003Cp>The United States (U.S.) Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your low-acid canned food (LACF) and snack food manufacturing facility, located at ST 9\u002F 2, 1 D\u002F 2, Sector 16-8 North Karachi Industrial Area, North Karachi, Sindh, Pakistan 75850 from October 21 to October 25, 2024. During that assessment, we found that you have serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation Part 113 (21 CFR 113). At the conclusion of the assessment, the FDA investigator issued you a listing of the observation actions. After reviewing the remote regulatory assessment findings and the responses you provided, we are issuing this letter to advise you of FDA's concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\u003Cp>As a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration, and filing of process information, and the mandatory requirements in 21 CFR Part 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35(k), for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your Guiab Jamu adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA's home page at www.fda.gov. FDA received your written response, describing corrective actions taken and planned by your firm, on November 12, 2024. After reviewing the inspectional findings and responses that you provided, we are issuing this letter to advise you of FDA's concerns and provide detailed information describing the findings at your facility. We address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Emergency Permit Control regulation, (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not provide evidence that the scheduled processes for the low-acid canned food products that you manufacture were established by a qualified person who has expert knowledge acquired through appropriate training and experience in thermal processing requirements for low-acid foods in hermetically sealed containers, as required by 21 CFR 113.83.\u003C\u002Fp>\u003Cp>Specifically, your scheduled process for Gulab Jamu was not established or overseen by a qualified person having the knowledge or experience of thermal processing requirements to determine the adequacy of your \"Heat Penetration and Heat Distribution Study for Gulab Jamun Retort Process\" where a single probe was used to determine the coldest spot in the product and retort.\u003C\u002Fp>\u003Cp>Your response states your staff has been registered for FDA approved Better Process School and that you have contacted local universities to conduct \"thorough heat distribution and Heat Penetration studies that uses multiple probes to accurately identify the coldest spots in both the product and the retort.\" You further state that refresher training will be performed on an annual basis and the \"Heat penetration &amp; heat distribution study\" will be reviewed every three years or as needed, \"in collaboration with the relevant university or training institution.\"\u003C\u002Fp>\u003Cp>We are unable to evaluate your corrective actions since you have not provided any completed training records and relevant validation or scientific studies for your manufacturing process.\u003C\u002Fp>\u003Cp>2. When a process was less than the scheduled process or when critical factors were out of control you did not either fully reprocess the portion of the production involved, keeping full records of the reprocessing conditions, or set aside the portion of the product involved for further evaluation as to any potential public health significance as required by 21 CFR 113.89.\u003C\u002Fp>\u003Cp>Specifically, your \"\u003Cstrong>(b)(4) \u003C\u002Fstrong>Process\" states that the product will be thermally processed at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> &nbsp;bar to reach an Fo value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the standard minimum Fo value listed as greater than or equal to 3. The manufacturing records reviewed during the inspection for Gulab Jamun manufactured on the dates of October 5 &amp; 24, 2024 and May 17, 2024, revealed Fo values below the standard minimum value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and further did not meet and maintain the critical requirements during the \u003Cstrong>(b)(4) \u003C\u002Fstrong>step which includes a minimum temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C\u003Cstrong> &nbsp;\u003C\u002Fstrong>with a pressure of \u003Cstrong>(b)(4) \u003C\u002Fstrong>bar for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes. For example, on May 17, 2024, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature only achieved \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> seconds and never achieved \u003Cstrong>(b)(4) \u003C\u002Fstrong>bar; on October 05, 2024 the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature never achieved \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C or \u003Cstrong>(b)(4)\u003C\u002Fstrong> bar; and on October 24, 2024 the \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature never achieved \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C and achieved \u003Cstrong>(b)(4)\u003C\u002Fstrong> bar for \u003Cstrong>(b)(4) \u003C\u002Fstrong>seconds.\u003C\u002Fp>\u003Cp>In your response you state, you immediately adjusted your process to use FDA approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> method to monitor critical factors in real time, hold non-conforming batches for evaluation and promised to send retention samples from the last \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches for microbiological analysis to a third-party lab. You also state the procedure for this product was inadequately written and did not clearly mention the critical limit and that your staff was untrained.\u003C\u002Fp>\u003Cp>Further, you state you will do the following: Develop and implement an SOP for identifying and handling deviations in retort processes including protocols for immediate identification of deviations from critical limits such as temperature, pressure and Fo, provide training to the operator and production supervisor conducting retort processes on how to recognize process deviations and document corrective actions, maintain records for temperature, pressure, and Fo values.\u003C\u002Fp>\u003Cp>We are unable to verify the adequacy of your corrective actions because you did not provide records or other information to review, demonstrating that you have established and followed FDA approved processes, provided third party lab test results, made corrections required when a deviation occurs, or any related employee training records.\u003C\u002Fp>\u003Cp>3. The initial temperature of the contents of the containers to be processed must be accurately determined and recorded with sufficient frequency to ensure that the temperature of the product is no lower than the minimum initial temperature specified in the scheduled process as required by 21 CFR 113.87(c). Specifically, the following initial temperature concerns were noted:\u003C\u002Fp>\u003Cp>You did not take the initial product temperature of the coldest can being processed but instead the last can loaded into the second of two retort trolleys after leaving a steam holding tunnel. Your procedures include \u003Cstrong>(b)(4)\u003C\u002Fstrong> which was used to take the initial temperature. On October 5, 2024, during the processing of Gulab Jamun this probe indicated an initial product temperature, identified as \u003Cstrong>(b)(4)\u003C\u002Fstrong>\", at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. This temperature was a deviation from the minimum initial temperature of 86.6°C, as specified in the filed scheduled process. This deviation was not identified by anyone at your facility. In addition, you have never identified a process deviation and did not maintain a deviation folder.\u003C\u002Fp>\u003Cp>Your response states an immediate adjustment to your procedure indicating you began measuring the initial temperature of the coldest can, not the last can loaded, to ensure compliance with the scheduled process. You also initiated a review of production management and batch sizes to prevent temperature discrepancies. Additionally, you stated you plan to do the following:\u003C\u002Fp>\u003Cp>Reduce batch sizes to align with the retort trolley's capacity to prevent recurrence temperature discrepancies during product loading; revise the SOP to specify that the initial temperature measurement must be taken from the coldest can in the retort trolley including steps for identifying the coldest can in the loading process; conduct a training session for the technicians on the importance of accurate initial temperature monitoring, procedural adherence, and the critical nature of recording from the coldest can; and implement a verification system requiring supervisory staff to review initial temperature records at the start of each batch, confirming adherence to monitoring points.\u003C\u002Fp>\u003Cp>We are unable to verify the adequacy of your corrective actions because you did not provide documents or other information demonstrating you are following an FDA approved scheduled process, identifying and correcting deviations when required, or employee training records.\u003C\u002Fp>\u003Cp>4. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 113.10.\u003C\u002Fp>\u003Cp>Specifically, our inspection revealed no one at your firm has attended Better Process School or similar training and experience to adequately understand the operations and monitoring required for low acid canned food manufacturing.\u003C\u002Fp>\u003Cp>In your response, you state this was not a requirement in Pakistan, but that you have added in part that you require the operator overseeing the retort operations attend FDA approved Better Process School. As a result, your Retort Operator, Quality Assurance and Production managers have been registered for this training.\u003C\u002Fp>\u003Cp>We are unable to verify your corrective actions because you have not provided any training certificates or other training documentation demonstrating training has been completed.\u003C\u002Fp>\u003Cp>The adequacy of your corrective actions will be verified during a future inspection. However, you did not provide any supporting evidence or an evaluation by your processing authority to address the products still on the market in the U.S. were manufactured in accordance with their scheduled process and safe for consumption. In your response to this Warning Letter, you should evaluate all lots of Gulab Jamun within shelf-life in the U.S. manufactured prior to October 25, 2024, to ensure they are commercially sterile. Please let us know if you intend to take any market action against this product.\u003C\u002Fp>\u003Cp>Failure to adequately address these violations may lead to regulatory action. For instance, we may take further action to refuse admission of your imported LACF &amp; snack food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the LACF food regulations (21 CFR 108 and 113) is Import Alert #99-38, \"Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control.\" This alert can be found on FDA's web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>We also offer the following comment\u003C\u002Fp>\u003Cp>Production records, including temperature-recording device records, must be signed, or initialed and dated by the reviewer. The retort continuous monitoring records you provided during the inspection for the Gulab Jamun were not signed or dated that they were reviewed by anyone at your facility to ensure the scheduled process was followed to prevent any public health concerns.\u003C\u002Fp>\u003Cp>For reference, temperature-recording device records must be identified by date, retort number, and other data as necessary, so they can be correlated with the record of lots processed. Each entry on the processing and production records must be made by the retort or processing system operator, or other designated person, at the time the specific retort or processing system or condition or operation occurs, and this retort or processing system operator or other designated person must sign or initial each record form. Not later than 1 working day after the actual process, and before shipment or release for distribution, a representative of plant management who is qualified by suitable training or experience must review all processing and production records for completeness and to ensure that the product received the scheduled process.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations at your facility or in connection with your products. You are responsible for investigating and determining the cause of the violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law including FDA regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Palmer, Compliance Officer, Office of Compliance and Enforcement, Office of Enforcement, Division of Conventional Foods Enforcement, 5001 Campus Drive, College Park, MD 20740. If you have any questions regarding this letter, you may contact Victoria Palmer via email at Victoria.palmer@fda.hhs.gov. Please reference Case# 698766 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A.\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery and Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Sheikh Muhammad Tehseen\n\nRecipient Title\n\nCEO\n\nUnited King Foods Private Limited\n\nIbrahim Residency, Plot 64, Block 3 C.P & B.C.H.S, Sharfabad Karachi\n\nSindh-75850\n\nPakistan\n\ntehseen@unitedking.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nMarch 7, 2025\nRe# 698766\nDear Mr. Sheikh Muhammad Tehseen:\nThe United States (U.S.) Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your low-acid canned food (LACF) and snack food manufacturing facility, located at ST 9\u002F 2, 1 D\u002F 2, Sector 16-8 North Karachi Industrial Area, North Karachi, Sindh, Pakistan 75850 from October 21 to October 25, 2024. During that assessment, we found that you have serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation Part 113 (21 CFR 113). At the conclusion of the assessment, the FDA investigator issued you a listing of the observation actions. After reviewing the remote regulatory assessment findings and the responses you provided, we are issuing this letter to advise you of FDA's concerns and to provide detailed information describing the findings at your facility.\nAs a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration, and filing of process information, and the mandatory requirements in 21 CFR Part 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35(k), for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your Guiab Jamu adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA's home page at www.fda.gov. FDA received your written response, describing corrective actions taken and planned by your firm, on November 12, 2024. After reviewing the inspectional findings and responses that you provided, we are issuing this letter to advise you of FDA's concerns and provide detailed information describing the findings at your facility. We address your response below.\nEmergency Permit Control regulation, (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113).\n1. You did not provide evidence that the scheduled processes for the low-acid canned food products that you manufacture were established by a qualified person who has expert knowledge acquired through appropriate training and experience in thermal processing requirements for low-acid foods in hermetically sealed containers, as required by 21 CFR 113.83.\nSpecifically, your scheduled process for Gulab Jamu was not established or overseen by a qualified person having the knowledge or experience of thermal processing requirements to determine the adequacy of your \"Heat Penetration and Heat Distribution Study for Gulab Jamun Retort Process\" where a single probe was used to determine the coldest spot in the product and retort.\nYour response states your staff has been registered for FDA approved Better Process School and that you have contacted local universities to conduct \"thorough heat distribution and Heat Penetration studies that uses multiple probes to accurately identify the coldest spots in both the product and the retort.\" You further state that refresher training will be performed on an annual basis and the \"Heat penetration & heat distribution study\" will be reviewed every three years or as needed, \"in collaboration with the relevant university or training institution.\"\nWe are unable to evaluate your corrective actions since you have not provided any completed training records and relevant validation or scientific studies for your manufacturing process.\n2. When a process was less than the scheduled process or when critical factors were out of control you did not either fully reprocess the portion of the production involved, keeping full records of the reprocessing conditions, or set aside the portion of the product involved for further evaluation as to any potential public health significance as required by 21 CFR 113.89.\nSpecifically, your \"(b)(4) Process\" states that the product will be thermally processed at (b)(4)°C for (b)(4) at (b)(4) bar to reach an Fo value of (b)(4) with the standard minimum Fo value listed as greater than or equal to 3. The manufacturing records reviewed during the inspection for Gulab Jamun manufactured on the dates of October 5 & 24, 2024 and May 17, 2024, revealed Fo values below the standard minimum value of (b)(4) and further did not meet and maintain the critical requirements during the (b)(4) step which includes a minimum temperature of (b)(4)°C with a pressure of (b)(4) bar for (b)(4) minutes. For example, on May 17, 2024, the (b)(4) temperature only achieved (b)(4)°C for (b)(4) and (b)(4) seconds and never achieved (b)(4) bar; on October 05, 2024 the (b)(4) temperature never achieved (b)(4)°C or (b)(4) bar; and on October 24, 2024 the (b)(4) temperature never achieved (b)(4)°C and achieved (b)(4) bar for (b)(4) seconds.\nIn your response you state, you immediately adjusted your process to use FDA approved (b)(4) method to monitor critical factors in real time, hold non-conforming batches for evaluation and promised to send retention samples from the last (b)(4) batches for microbiological analysis to a third-party lab. You also state the procedure for this product was inadequately written and did not clearly mention the critical limit and that your staff was untrained.\nFurther, you state you will do the following: Develop and implement an SOP for identifying and handling deviations in retort processes including protocols for immediate identification of deviations from critical limits such as temperature, pressure and Fo, provide training to the operator and production supervisor conducting retort processes on how to recognize process deviations and document corrective actions, maintain records for temperature, pressure, and Fo values.\nWe are unable to verify the adequacy of your corrective actions because you did not provide records or other information to review, demonstrating that you have established and followed FDA approved processes, provided third party lab test results, made corrections required when a deviation occurs, or any related employee training records.\n3. The initial temperature of the contents of the containers to be processed must be accurately determined and recorded with sufficient frequency to ensure that the temperature of the product is no lower than the minimum initial temperature specified in the scheduled process as required by 21 CFR 113.87(c). Specifically, the following initial temperature concerns were noted:\nYou did not take the initial product temperature of the coldest can being processed but instead the last can loaded into the second of two retort trolleys after leaving a steam holding tunnel. Your procedures include (b)(4) which was used to take the initial temperature. On October 5, 2024, during the processing of Gulab Jamun this probe indicated an initial product temperature, identified as (b)(4)\", at (b)(4)°C. This temperature was a deviation from the minimum initial temperature of 86.6°C, as specified in the filed scheduled process. This deviation was not identified by anyone at your facility. In addition, you have never identified a process deviation and did not maintain a deviation folder.\nYour response states an immediate adjustment to your procedure indicating you began measuring the initial temperature of the coldest can, not the last can loaded, to ensure compliance with the scheduled process. You also initiated a review of production management and batch sizes to prevent temperature discrepancies. Additionally, you stated you plan to do the following:\nReduce batch sizes to align with the retort trolley's capacity to prevent recurrence temperature discrepancies during product loading; revise the SOP to specify that the initial temperature measurement must be taken from the coldest can in the retort trolley including steps for identifying the coldest can in the loading process; conduct a training session for the technicians on the importance of accurate initial temperature monitoring, procedural adherence, and the critical nature of recording from the coldest can; and implement a verification system requiring supervisory staff to review initial temperature records at the start of each batch, confirming adherence to monitoring points.\nWe are unable to verify the adequacy of your corrective actions because you did not provide documents or other information demonstrating you are following an FDA approved scheduled process, identifying and correcting deviations when required, or employee training records.\n4. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 113.10.\nSpecifically, our inspection revealed no one at your firm has attended Better Process School or similar training and experience to adequately understand the operations and monitoring required for low acid canned food manufacturing.\nIn your response, you state this was not a requirement in Pakistan, but that you have added in part that you require the operator overseeing the retort operations attend FDA approved Better Process School. As a result, your Retort Operator, Quality Assurance and Production managers have been registered for this training.\nWe are unable to verify your corrective actions because you have not provided any training certificates or other training documentation demonstrating training has been completed.\nThe adequacy of your corrective actions will be verified during a future inspection. However, you did not provide any supporting evidence or an evaluation by your processing authority to address the products still on the market in the U.S. were manufactured in accordance with their scheduled process and safe for consumption. In your response to this Warning Letter, you should evaluate all lots of Gulab Jamun within shelf-life in the U.S. manufactured prior to October 25, 2024, to ensure they are commercially sterile. Please let us know if you intend to take any market action against this product.\nFailure to adequately address these violations may lead to regulatory action. For instance, we may take further action to refuse admission of your imported LACF & snack food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the LACF food regulations (21 CFR 108 and 113) is Import Alert #99-38, \"Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control.\" This alert can be found on FDA's web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nWe also offer the following comment\nProduction records, including temperature-recording device records, must be signed, or initialed and dated by the reviewer. The retort continuous monitoring records you provided during the inspection for the Gulab Jamun were not signed or dated that they were reviewed by anyone at your facility to ensure the scheduled process was followed to prevent any public health concerns.\nFor reference, temperature-recording device records must be identified by date, retort number, and other data as necessary, so they can be correlated with the record of lots processed. Each entry on the processing and production records must be made by the retort or processing system operator, or other designated person, at the time the specific retort or processing system or condition or operation occurs, and this retort or processing system operator or other designated person must sign or initial each record form. Not later than 1 working day after the actual process, and before shipment or release for distribution, a representative of plant management who is qualified by suitable training or experience must review all processing and production records for completeness and to ensure that the product received the scheduled process.\nThis letter is not intended to be an all-inclusive statement of violations at your facility or in connection with your products. You are responsible for investigating and determining the cause of the violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law including FDA regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Palmer, Compliance Officer, Office of Compliance and Enforcement, Office of Enforcement, Division of Conventional Foods Enforcement, 5001 Campus Drive, College Park, MD 20740. If you have any questions regarding this letter, you may contact Victoria Palmer via email at Victoria.palmer@fda.hhs.gov. Please reference Case# 698766 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A.\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","United King Foods Private Limited","united-king-foods-private-limited-698766-03072025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funited-king-foods-private-limited-698766-03072025","2026-10-26T08:10:17.782493+00:00","2025-06-03","698766","Food & Beverages","Mr. Sheikh Muhammad Tehseen","2026-08-19T16:43:34.596+00:00","Via Express Delivery and Electronic Mail","2025-03-07",4,{"510k":98,"classification":99,"enforcement":100,"event":101,"event_backfill":102,"pma":103,"warning_letter":104},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]